Qlucore Ab (Publ)
QCORE.ST
Stockholm Stock Exchange0.45
SEK
-0.01
- -
Qlucore Ab (Publ)
QCORE.ST
(Stockholm Stock Exchange)
Recent
price
0.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Qlucore AB (publ) (Ticker: QCORE.ST) develops and markets visualization-based bioinformatics software for research, precision diagnostics and companion diagnostics in the life sciences, biotech, academia and healthcare sectors. The company's core products include Qlucore Omics Explorer, an interactive tool for analyzing high-dimensional omics data such as microarray gene expression, RNA-seq, NGS, proteomics and metabolomics on standard PCs or Macs; Qlucore Insights, a research-use-only platform for clinical data analysis with AI-powered machine learning models; and Qlucore Diagnostics, a CE-marked IVDR-compliant software platform featuring multi-omics companion diagnostics, including the first approved RNA-seq-based test for pediatric leukemia (BCP-ALL) and models for lung cancer analysis from fixed tissue, embedded specimens or fine-needle biopsies. Qlucore Omics Explorer supports real-time 3D visualization, dynamic genome browsers, statistical analysis and heatmaps for data exploration up to 100 million samples; Qlucore Diagnostics and Insights integrate disease-specific classifiers, patient visualizations and report generation for precision oncology. Founded in 2007 as a Lund University spin-out and headquartered at Ideon Science Park in Lund, Sweden, the company operates globally with customers in approximately 20 countries, sales offices in Europe and North America, a U.S. subsidiary handling American markets, and distribution partners in Asia; it listed on Nasdaq First North Growth Market in 2021 following a SEK 30 million pre-IPO funding round led by Eiffel Investment Group. Recent developments include the launch of its first CE-marked pediatric leukemia diagnostic test in 2025, sales of Qlucore Diagnostics and Insights to Mubadala Health Dubai and two major Nordic hospitals including Sahlgrenska University Hospital post-Q2 2025, a fully subscribed rights issue raising net SEK 14.3 million in H2 2025 to fund sales expansion and cost efficiencies, issuance of 1,035,000 employee warrants in October 2025 exercisable through 2029, personnel reductions to 12 full-time equivalents by October 2025 achieving 34% quarterly cost savings excluding non-cash items, and discontinuation of the Qlucore Omics Explorer cloud solution with related intangible asset impairments of SEK 19.5 million in Q2 2025.